ClinicalTrials.Veeva

Menu

Suitability of a High-energy, Low-protein Formula (Renalive® LP)

Fresenius Kabi logo

Fresenius Kabi

Status

Enrolling

Conditions

Low Protein Dietary Intake
CKD
Malnutrition (Calorie)

Treatments

Dietary Supplement: Renalive® LP,

Study type

Interventional

Funder types

Industry

Identifiers

NCT06892249
Rena-001-CEN

Details and patient eligibility

About

Inclusion criteria (1) Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR<45 mL/min/1.73 m2)

Exclusion criteria

(1) Has received dialysis or are expected to start dialysis within the next 3 months.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

(1) Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR<45 mL/min/1.73 m2)

Exclusion criteria

(1) Has received dialysis or are expected to start dialysis within the next 3 months

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

80 participants in 1 patient group

Renalive® LP
Experimental group
Treatment:
Dietary Supplement: Renalive® LP,

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems